Intuitive Surgical, Inc. vs Tempus AI — how do they compare? Intuitive Surgical, Inc. trades at $415.51 (market cap $146.44B), while Tempus AI trades at $69.99 (market cap $12.77B). The key difference: Intuitive Surgical, Inc. is far larger — about 11.5× Tempus AI's market cap, and Tempus AI is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Tempus AI for 22 Days on average.
| ISRG | TEM | |
|---|---|---|
Market Cap | $146.44B | $12.77B |
Volume | 1,895,430 | 8,980,490 |
Sector | Health | Broad Market / Factor |
52-Week High | $592.85 | $99.28 |
52-Week Low | $332.02 | $41.55 |
Typical Hold Time | 84 Days | 22 Days |
Enterprise Value | $141.22B | $13.40B |
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $415.41, up 2.63% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $10.06B and net income of $2.86B, maintaining impressive 28.45% net margins. Recent earnings beats and expansion into new markets like India and Japan support growth despite China headwinds. Technical indicators show the stock trading near pivot point resistance at $414 with support at $411.
ISRG presents a compelling growth story with dominant robotics positioning and expanding international footprint. The 17% selloff creates opportunity with 16% upside to consensus target of $480.78. Key risks include competitive pressures in robotic surgery and procedure growth normalization. Analyst consensus remains strongly bullish with 70% buy ratings, though valuation multiples remain elevated at P/E of 47.54.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →